9 Things to Know About the Upcoming ~$1.9 Billion Enfusion (ENFN) IPO

Enfusion, Inc. (NYSE: ENFN), a global, high-growth SaaS provider, designed to eliminate technology and information barriers, empowering investment managers to confidently make and execute better-informed investment decisions in real-time, is due to launch its U.S. stock IPO next week. Here are 9 key things to consider about the upcoming Enfusion IPO.

1. Enfusion IPO Date – Enfusion, Inc. is due to go public on 10/21. Enfusion will start trading under the ticker symbol “ENFN” on the New York Stock Exchange (NYSE). Generally, shares that make their public stock market debuts start trading between 10 AM - 2 PM ET.

2. Enfusion IPO Pricing - Enfusion expects to price its shares between $15.00 and $17.00.

3. Shares Offered - 18,750,000 total shares offered. Enfusion is looking to sell 15,322,660 shares of our Class A common stock, plus 3,427,340 shares of Class A common offered by the selling stockholders. The S-1 filing shows the number of outstanding shares after IPO offering would be 113,054,261.

4. Enfusion IPO Valuation - Enfusion is seeking a valuation of between $1.696 billion and $1.922 billion.

5. Enfusion IPO Raised Proceeds: At the midpoint of the pricing range, Enfusion is looking to raise $245.15 million for itself.

6. Enfusion IPO Underwriters - Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC are acting as lead book-running managers for the proposed offering, with BofA Securities, Credit Suisse Securities (USA) LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and William Blair & Company, L.L.C. acting as additional book-runners, and Loop Capital Markets acting as co-manager.

7. Enfusion Financials - Enfusion generated sales of $50.8 million for the first six months of the year. Profit came in at $8.4 million. Grown Annual Recurring Revenue from $33.1 million for the month ended December 31, 2017 to $93.4 million for the month ended December 31, 2020 (representing a compound annual growth rate of 41.4%).

8. Enfusion Ownership - Two largest shareholders are Oleg Movchan with a 12.8% stake in the company after the IPO, and Malherbe Investments LLC (10.9%).

9. Enfusion Total Addressable Market (TAM): Enfusion estimates its total addressable market in excess of $19 billion.

You May Also Be Interested In

• Chinese bubble tea company Chabaidao sees shares tumble in Hong Kong market debut
• Rubrik IPO: 5 key things to know
• Stifel Downgrades Saipem (SPM:IM) (SAPMY) to Hold